Ocular complications in atopic dermatitis and a case study of a patient with severe ocular complications treated with dupilumab

Abstract

Atopic dermatitis is a chronic multifactorial inflammatory skin disease with a prevalence of 1-3% in adults and 15-20% in the world pediatric population that poses a significant burden on patients' quality of life. In recent years, increasing evidence of ocular complications (conjunctivitis, keratitis, keratoconus and others) in patients with atopic dermatitis has accumulated.

The first biologic therapy, dupilumab, has been approved for the treatment of atopic dermatitis. Higher incidence of conjunctivitis was reported in clinical trials compared with placebo.

Unfortunately, it is not yet known how to manage patients with pre-existing ophthalmological impairment. In this article, we describe a case of a patient with severe atopic dermatitis and severe ocular complications undergoing treatment with dupilumab.

The skin manifestations have significantly improved and the ophthalmological finding is still stable even several months after the initiation of the biologic treatment.